The biology of non-small-cell lung cancer: Identifying new targets for rational therapy

Lung Cancer

Volumn 46, Issue 2, 2004, Pages 135-148

  Rosell, R ^a   Felip, E ^b   Garcia Campelo, R ^c   Balana C ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Biology of neoplasia; Non small cell lung cancer; Pharmacogenetics; Targeted therapy

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; GEMCITABINE; ISIS 3521; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PENTAGLUTAMATE; PLATINUM; PRINOMASTAT; PROTEIN KINASE C INHIBITOR; REBIMASTAT; STAUROSPORINE; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DNA ADDUCT; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; GENETIC MARKER; HEMOPTYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PHARMACOGENOMICS; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE THERAPY; GENETIC MARKERS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 4944221276     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.031     Document Type: Review

References (95)

1. Giovino G.A. Epidemiology of tobacco use in the United States. Oncogene. 21:2002;7326-7340
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999, National Cancer Institute, Bethesda, MD. Available at: http://www.seer.cancer.gov/csr/1973_1999/, 2002. Accessed February 2003.
3. Wistuba I.I., Mao L., Gazdar A.F. Smoking molecular damage in bronchial epithelium. Oncogene. 21:2002;7298-7306
4. Nacht M., Dracheva T., Gao Y., et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA. 98:2001;15203-15208
5. Osada H., Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 21:2002;7421-7434
6. Mao L. Recent advances in the molecular diagnosis of lung cancer. Oncogene. 21:2002;6960-6969
7. Soria J.C., Xu X., Liu D.D., et al. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 95:2003;165-168
8. Sanchez-Cespedes M., Monzo M., Rosell R. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol. 9:1998;113-116
9. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70
10. Sozzi G., Conte D., Mariani L., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:2001;4675-4678
11. Ramirez J.L., Sarries C., Lopez de Castro P., et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193:2003;207-216
12. Rodenhuis S., van de Wetering M.L., Mooi W.J., Evers S.G., Van Zandwijk N., Bos J.L. Mutational activation of the K-ras oncogene. A possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med. 317:1987;929-935
13. Slebos R.J., Kibbelaar R.E., Dalesio O., et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 323:1990;561-565
14. Mitsudomi T., Steinberg S.M., Oie H.K., et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51:1991;4999-5002
15. Rosell R., Li S., Skacel Z., et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 8:1993;2407-2412
16. Nelson H.H., Christiani D.C., Mark E.J., Wiencke J.K., Wain J.C., Kelsey K.T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst. 91:1999;2032-2038
17. Graziano S.L., Gamble G.P., Newman N.B., et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 17:1999;668-675
18. Schiller J.H., Adak S., Feins R.H., et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 19:2001;448-457
19. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Eng J Med. 330:1994;153-158
20. Broermann P., Junker K., Brandt B.H., et al. Trimodality treatment in stage III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer. 94:2002;2055-2062
21. Khuri F.R., Lotan R., Kemp B.L., et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol. 18:2000;2798-2804
22. Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 5:1999;1001-1005
23. Khuri F.R., Wu H., Lee J.J., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 7:2001;861-867
24. Tang X., Khuri F.R., Lee J.J., et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 92:2000;1511-1516
25. Burbee D.G., Forgacs E., Zöchbauer-Müller S., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 93:2001;691-699
26. Shih J.Y., Yang S.C., Hong T.M., et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst. 93:2001;1392-1400
27. Yuan A., Yang P.C., Yu C.J., et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 162:2000;1957-1963
28. Soria J.C., Moon C., Kemp B.L., et al. Lack of interleukin-10 could predict poor outcome in patients with stage I non-small-cell lung cancer. Clin Cancer Res. 9:2003;1785-1791
29. Tomiyasu M., Yoshino I., Suemitsu R., Okamato T., Sugimachi K. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res. 8:2002;3755-3760
30. Moran C.J., Arenberg D.A., Huang C.C., et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 8:2002;3803-3812
31. Chang Y.S., Wang L., Liu D., et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res. 8:2002;3669-3675
32. Bepler G., Gautam A., McIntyre L.M., et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol. 20:2002;1353-1360
33. Simon G., Sharma S., Smith P., Bepler G. Increased ERCC1 expression predicts for improved survival in resected patients with non-small-cell lung cancer (NSCLC). Eur J Cancer. 38(Suppl):2002;S15
34. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet. 33:2003;49-54
35. Blommaert F.A., Michael C., Terheggen P.M., et al. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy. Cancer Res. 53:1993;5669-5675
36. Schellens J.H., Ma J., Planting A.S., et al. Relationship between the exposure to cisplatin. Br J Cancer. 73:1996;1569-1675
37. Schaake-Koning C., Van den Boagert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 326:1992;524-530
38. van de Vaart P.J., Belderbos J., de Jong D., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 89:2000;160-166
39. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62:2002;4899-4902
40. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:2004;1318-1325
41. Danesi R., De Braud F., Fogli S., et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev. 55:2003;57-103
42. Nakagawa T., Otake Y., Yanagihara K., et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer. 43:2004;145-149
43. Shintani Y., Ohta M., Hirabayashi H., et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer. 104:2003;790-795
44. Fukushima M., Morita M., Ikeda K., Nagayama S. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med. 12:2003;839-844
45. Hughes A., Calvert P., Azzabi A., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 20:2002;3533-3544
46. Rusthoven J.J., Eisenhauer E., Butts C., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 17:1999;1194-1199
47. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol. 13:2002;737-741
48. Smit E.F., Mattson K., Von Pawel J., et al. Alimta (pemetrexed disodium) a second line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol. 14:2003;455-460
49. Hanna N.H., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:2004;1589-1597
50. Thödtmann R., Depenbrock H. Dumez and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 10:1999;3009-3016
51. Manegold C., Gatzemeier U., von Pawel J., et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 11:2000;435-440
52. Shepherd F.A., Dancey J., Arnold A., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 92:2001;595-600
53. Scagliotti G., Kortsik C., Castellano D., et al. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol. 22:2003;625. (abstract 2513)
54. Zinner R., Obasaju C.K., Fossella F.V., et al. Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): a phase II trial. Proc Am Soc Clin Oncol. 22:2003;642. (abstract 2580)
55. Curtin N.J., Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2:2001;298-306
56. Niyikiza C., Baker S.D., Seitz D.E., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Therap. 1:2002;545-552
57. Sarries C., Haura E.B., Roig B., et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics. 3:2002;763-780
58. Rosell R., Crino L. Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncol. 29(2 Suppl 5):2002;23-29
59. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer. 82:2000;1427-1432
60. DeVore R.F., Fehrenbacher L., Herbst R.S., et al. A randomized phase II trial comparing RhuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol. 19:2000;485a. (abstract 1896.)
61. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 20:2002;4434-4439
62. Coussens L.M., Finglenton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2002;2387-2392
63. Salomon D.S., Brandt R., Ciardello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol. 19:1995;183-232
64. Mendelsohn J. Blockade of receptors from growth factors: an anticancer therapy. Clin Cancer Res. 6:2000;747-753
65. Rosell R., Fosella F., Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer. 38(1Suppl):2002;43-49
66. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2002;2240-2250
67. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2002;2237-2246
68. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of XD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;292a. (abstract 1166)
69. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 1. J Clin Oncol. 22:2004;777-784
70. Herbst R., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 22:2004;785-794
71. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
72. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 20:2001;310a. (abstract 1235)
73. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 59:1993;257-280
74. Wang S., Vrana J.A., Bartimole T.M., et al. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D- arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 52:1997;1000-1009
75. Dean N.M., McKay R., Condon T.P., Bennett C.F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 269:1994;16416-16424
76. Nemunaitis J., Holmlund J.T., Kraynak M., et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol. 17:1999;3586-3595
77. Yuen A.R., Halsey J., Fisher G.A., et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 5:1999;3357-3363
78. Yuen A., Halsey J., Fisher G., et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small-cell lung cancer. Proc Am Soc Clin Oncol. 20:2001;309a
79. Ritch P.S., Belt R., George S., et al. Phase I/II trial of ISIS 3512/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 21:2002;309a
80. Moore M.R., Saleh M., Jones C.M., et al. Phase II trial of ISIS 3512/LY900003, an antisense inhibitor of PKC-alpha, with docetaxel in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 21:2002;297a
81. Shen L N.M., Glazer R.I. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase C alpha antisense oligonucleotide. Mol Pharmacol. 55:1999;396-402
82. Hidalgo M L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
83. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 20:2001;310a. (abstract 1235)
84. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 15:2004;19-27
85. Zinner R.G., Glisson B.S., Fossella F.V., et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 44:2004;99-110
86. Swisher S.G., Roth J.A., Nemunaitis J., et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;763-771
87. Chan D.C., Earle K.A., Zhao T.L., et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 8:2002;904-912
88. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenoma subclasses. Proc Natl Acad Sci USA. 98:2001;13790-13795
89. Menon L.G., Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 95:1995;221-225
90. Chen H.W., Yu S.L., Chen J.J., et al. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol. 65:2004;99-110
91. Zembutsu H., Ohnishi Y., Tsunoda T., et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527
92. Dan S., Tsunoda T., Kitahara O., et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:2002;1139-1147
93. Kikuchi T., Daigo Y., Katagiri T., et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 22:2003;2192-2205
94. Scherf U., Ross D.T., Waltham M., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 24:2000;236-244
95. Franklin W.A., Carbone D.P. Molecular staging and pharmacogenomics. Clinical implications: from lab to patients and back. Lung Cancer. 41(Suppl 1):2003;S147-S154